Contact
Please use this form to send email to PR contact of this press release:
Positive Q1 Results Posted After Clinical Trial Delivers Statistically-Significant Data for Bipolar: NRx: Nasdaq: NRXP
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134